Skip to main content

Advertisement

SpringerLink
Log in

High-mobility group box 1 in multiple sclerosis

  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

This study is one in series determining the potential of RAGE axis (receptor for advanced glycation end products, isoforms, ligands) as a biomarker in multiple sclerosis (MS). We evaluated serum levels of RAGE ligand, the high-mobility group box (HMGB)1 in MS patients, and assessed the correlation between HMGB1 serum levels and the use of disease-modifying drugs (DMDs), and between HMGB1 serum levels and indicators of MS disease severity. HMGB1 serum levels were compared between 96 (23 males) MS patients and 34 age- and gender-matched healthy controls (HCs) using enzyme-linked immunosorbent assays. DMD-naïve MS patients had significantly higher HMGB1 serum levels compared with DMD-treated (P = 0.04) and compared with HCs (P = 0.01). HMGB1 serum levels were not significantly different between total MS patients (DMD-naïve plus DMD-treated) and HCs (P = 0.09). DMD-naïve MS patients in clinical relapse tended to have lower HMGB1 serum levels than clinically stable RRMS patients (P = 0.07). HMGB1 serum levels showed 0.65 area under the curve (95 % CI 0.55–0.95) sensitivity/specificity for MS clinical relapse. The role of HMGB1 in MS disease pathology and DMD modulation of this protein warrant further investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. van Noort JM, Baker D, Amor S. Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors. CNS Neurol Disord Drug Targets. 2012;11:556–69.

    Article  PubMed  Google Scholar 

  2. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem. 2009;16:940–52.

    Article  CAS  PubMed  Google Scholar 

  3. Sternberg Z, Hennies C, Sternberg D, Wang P, Kinkel P, Hojnacki D, Weinstock-Guttmann B, Munschauer F. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. J Neuroinflammation. 2010;7:72.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sternberg Z, Hennies C, Sternberg D, Bistulfi GL, Kazim L, Benedict RH, Chadha K, Leung C, Weinstock-Guttman B, Munschauer F. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Mult Scler. 2011;17:157–63.

    Article  PubMed  Google Scholar 

  5. Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, Lieberman A, Kazim L, Drake A, Rocco P, Grazioli E, Munschauer F. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler. 2008;14:759–63.

    Article  CAS  PubMed  Google Scholar 

  6. Sternberg Z, Sternberg D, Drake A, Chichelli T, Yu J, Hojnacki D. Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis. J Neuroimmunol. 2015. doi:10.1016/j.jneuroim.2014.07.005.

  7. West KL, Castellini MA, Duncan MK, Bustin M. Chromosomal proteins HMGN3a and HMGN3b regulate the expression of glycine transporter 1. Mol Cell Biol. 2004;24:3747–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMGB-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–51.

    Article  CAS  PubMed  Google Scholar 

  9. Sundberg E, Fasth AE, Palmblad K, Harris HE, Andersson U. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology. 2009;214:303–9.

    Article  CAS  PubMed  Google Scholar 

  10. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005;174:7506–15.

    Article  CAS  PubMed  Google Scholar 

  11. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279:7370–7.

    Article  CAS  PubMed  Google Scholar 

  12. Chen KB, Uchida K, Nakajima H, Yayama T, Hirai T, Rodriguez Guerrero A, Kobayashi S, Ma WY, Liu SY, Zhu P, Baba H. High-mobility group box-1 and its receptors contribute to proinflammatory response in the acute phase of spinal cord injury in rats. Spine. 2011;36:2122–9.

    Article  PubMed  Google Scholar 

  13. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 2003;284:C870–9.

    Article  CAS  PubMed  Google Scholar 

  15. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101:2652–60.

    Article  CAS  PubMed  Google Scholar 

  16. Kawabata H, Setoguchi T, Yone K, Souda M, Yoshida H, Kawahara K, Maruyama I, Komiya S. High mobility group box 1 is upregulated after spinal cord injury and is associated with neuronal cell apoptosis. Spine. 2010;35:1109–15.

    Article  PubMed  Google Scholar 

  17. Vogelgesang A, May VE, Grunwald U, Bakkeboe M, Langner S, Wallaschofski H, Kessler C, Broker BM, Dressel A. Functional status of peripheral blood T-cells in ischemic stroke patients. PLoS One. 2010;5:e8718.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ, Bendszus M, Rossetti G, Nawroth PP, Bierhaus A, Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci. 2008;28:12023–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005;33:564–73.

    Article  CAS  PubMed  Google Scholar 

  20. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med. 2008;14:109–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, Huston BJ, Chavan S, Rosas-Ballina M, Gregersen PK, Czura CJ, Sloan RP, Sama AE, Tracey KJ. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med. 2007;13:210–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int. 2012;32:395–402.

    Article  CAS  PubMed  Google Scholar 

  23. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003;48:971–81.

    Article  CAS  PubMed  Google Scholar 

  24. Wang H, Wang K, Wang C, Xu F, Zhong X, Qiu W, Hu X. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. NeuroImmunoModulation. 2013;20:113–8.

    Article  PubMed  Google Scholar 

  25. Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallstrom E, Lobell A, Brundin L, Lassmann H, Harris RA. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008;84:1248–55.

    Article  CAS  PubMed  Google Scholar 

  26. Uzawa A, Mori M, Taniguchi J, Masuda S, Muto M, Kuwabara S. Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2013;172:37–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005;61:1–9.

    Article  CAS  PubMed  Google Scholar 

  28. Kim JH, Kim SJ, Lee IS, Lee MS, Uematsu S, Akira S, Oh KI. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway. J Immunol. 2009;182:2458–66.

    Article  CAS  PubMed  Google Scholar 

  29. Henig N, Avidan N, Mandel I, Staun-Ram E, Ginzburg E, Paperna T, Pinter RY, Miller A. Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells. PLoS One. 2013;8:e62366.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D. Disease modifying therapies modulate cardiovascular risk factors in multiple sclerosis patients. Cardiovasc Ther. 2013. doi:10.1111/1755-5922.12049.

  31. Grossin N, Boulanger E, Wautier MP, Wautier JL. The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents. Clin Hemorheol Microcirc. 2010;45:143–53.

    CAS  PubMed  Google Scholar 

  32. Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, Ueda S, Nakamura K, Okuda S. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metab Clin Exp. 2012;61:1067–72.

    Article  CAS  PubMed  Google Scholar 

  33. Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol. 2007;33:86–98.

    Article  CAS  PubMed  Google Scholar 

  34. Agnello D, Wang H, Yang H, Tracey KJ, Ghezzi P. HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine. 2002;18:231–6.

    Article  CAS  PubMed  Google Scholar 

  35. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22:5551–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rong LL, Trojaborg W, Qu W, Kostov K, Yan SD, Gooch C, Szabolcs M, Hays AP, Schmidt AM. Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J. 2004;18:1812–7.

    Article  CAS  PubMed  Google Scholar 

  37. Roussel BD, Mysiorek C, Rouhiainen A, Jullienne A, Parcq J, Hommet Y, Culot M, Berezowski V, Cecchelli R, Rauvala H, Vivien D, Ali C. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. J Cell Sci. 2011;124:2070–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank nurse and staff of Baird MS center for blood draw, and Dr. Husam Ghanim for the intellectual input. This study was supported in part by a grant from National Multiple Sclerosis Society (NMSS PP1402).

Conflict of interest

None.

Ethical standard

Authors confirm that the ethical standards recommended by the Helsinki Declaration have been met.

Author information

Authors and Affiliations

  1. Department of Neurology, Baird MS Center, Jacobs Neurological Institute, Buffalo, NY, USA

    Zohara Sternberg, Daniel Sternberg, Trevor Chichelli, Allison Drake, Chana Kolb & David Hojnacki

  2. Department of Molecular and Cell Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

    Neel Patel & Kailash Chadha

  3. Department of Biostatistics, University of Buffalo, Buffalo, NY, USA

    Jinhee Yu

Authors
  1. Zohara Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Trevor Chichelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Allison Drake
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neel Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chana Kolb
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kailash Chadha
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jinhee Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David Hojnacki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zohara Sternberg.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sternberg, Z., Sternberg, D., Chichelli, T. et al. High-mobility group box 1 in multiple sclerosis. Immunol Res 64, 385–391 (2016). https://doi.org/10.1007/s12026-015-8673-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-015-8673-x

Keywords

Search

Navigation